Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 10/20 | 0.55 |
| ▸ | JAK1 | P23458 | 8/20 | 0.55 |
| ▸ | GAA | P10253 | 7/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13925597 | 0.85 | JAK2 (0.51) | JAK2JAK1GAAKMT2AS1PR4 | |
| SCHEMBL4627041 | 0.84 | JAK2 (0.50) | JAK2JAK1GAATYK2JAK3 | |
| SCHEMBL13925603 | 0.84 | JAK2 (0.46) | JAK2JAK1TYK2JAK3KMT2A | |
| SCHEMBL13925602 | 0.80 | JAK2 (0.43) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL4188172 | 0.79 | JAK2 (0.49) | JAK2JAK1GAATYK2JAK3 | |
| SCHEMBL13925604 | 0.79 | JAK2 (0.58) | JAK2JAK1GAATYK2JAK3 | |
| SCHEMBL13925601 | 0.78 | KDR (0.44) | JAK2JAK1TYK2JAK3ALDH1A1 | |
| SCHEMBL4894925 | 0.77 | MAPK1 (0.54) | JAK2JAK1S1PR4ALDH1A1MAPT | |
| SCHEMBL13925600 | 0.77 | KDR (0.44) | JAK2JAK1GAAKMT2AALDH1A1 | |
| SCHEMBL13925599 | 0.76 | ROCK2 (0.50) | JAK2JAK1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036508-A1 | AMINO INDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-02-05 | — | — | US | disclosed |
| US-20090036508-A1 | AMINO INDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-02-05 | — | — | US | disclosed |
| US-20090036508-A1 | AMINO INDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-02-05 | — | — | US | disclosed |
| WO-2007090494-A1 | AMINO INDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036508-A1 | AMINO INDAZOLE DERIVATIVES | CHEK1, CHEK2, SGK3 | JAK2 559/4885JAK1 523/4885GAA 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.